Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Fredun Pharmaceuticals 9-Day RSI Related Terms
BOM:539730 vs ZTS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fredun Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fredun Pharmaceuticals 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fredun Pharmaceuticals's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Fredun Pharmaceuticals's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fredun Pharmaceuticals (BOM:539730) has a 9-Day RSI of 82.73 as of Aug. 05, 2026. According to the industry distribution chart, Fredun Pharmaceuticals ranks #1031 out of 1048 companies in the Drug Manufacturers industry, placing it in the top 98.4%.
Is Fredun Pharmaceuticals' 9-Day RSI too high?
Fredun Pharmaceuticals' current 9-Day RSI is 82.73. The Drug Manufacturers industry median 9-Day RSI is 51.11. Fredun Pharmaceuticals' value of 82.73 is 61.9% above this industry median. Based on the distribution chart, Fredun Pharmaceuticals ranks #1031 out of 1048 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Fredun Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' 9-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fredun Pharmaceuticals ranks #1031 out of 1048 companies for 9-Day RSI. This places Fredun Pharmaceuticals in the lower half of its industry. The industry median 9-Day RSI is 51.11. Fredun Pharmaceuticals' value of 82.73 is 61.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 51.11, based on 1,048 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fredun Pharmaceuticals's current 9-Day RSI of 82.73 is 61.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 51.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fredun Pharmaceuticals's current 9-Day RSI is 82.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (BOM:539730) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹536.17, compared to a current price of ₹1,109.75 — trading 107% above its estimated fair value. The current 9-Day RSI is 82.73 and 61.9% above the Drug Manufacturers industry median of 51.11. Fredun Pharmaceuticals' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Fredun Pharmaceuticals (BOM:539730), the current 9-Day RSI is 82.73 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fredun Pharmaceuticals (BOM:539730) Overvalued in 2026?
Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹1,109.75 is trading 107% above its estimated GF Value™ of ₹536.17.
GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:539730:
9-Day RSI: 82.73
GF Value™: ₹536.17 vs. price of ₹1,109.75 (107% above fair value)
Industry Position: 61.9% above the Drug Manufacturers median (#1031 of 1048)
No single metric tells the full story. See the BOM:539730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
67GF Score
Get the complete analysis for BOM:539730
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539730 has been successfully added to your 
